Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.24 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and emphasized the need for strategic adjustments. There was no specific guidance provided for future performance.
Management did not provide specific guidance for future quarters.
The company is focusing on improving operational efficiencies.
Veracyte's earnings report indicates challenges in achieving profitability, as reflected in the negative EPS. The stock dropped 5.66% following the announcement, likely due to investor concerns over the lack of revenue details and future guidance. The management's cautious tone suggests that the company is navigating a tough market environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
May 1, 2017